Pharmaceutical manufacturer AstraZeneca has published stronger than expected revenues – in the last quarter, revenue for AstraZeneca fell by about a fifth to $6.68 billion. In particular, generic competition and patent expirations have reduced revenues massively. After nine months, sales fell by 17 per cent to $20.69 billion.
Core earnings for the Swedish-British company amounted to $1.51 per share, a decline of 12 percent. The new CEO Pascal Soriot is now looking for ways to accelerate the development of new revenue sources. The future strategy will be presented in the first quarter of 2013.
[ilink url=“http://www.astrazeneca.com/Media/Press-releases/Article/20121025–astrazeneca-plc-third-quarter-results-2012″] Link zur Quelle (AstraZeneca)[/ilink]